Halozyme provides preliminary 2025 revenue estimates

Halozyme Therapeutics Inc. (NASDAQ: HALO) provided preliminary financial estimates for 2025 during a January 28 investor conference call and press release.

The company estimated 2025 revenue in the range of $1.385 billion to $1.4 billion. Royalties are projected between $865 million and $870 million, while product sales are estimated at $372 million to $377 million. Collaboration revenue is expected to range from $148 million to $153 million.

The figures represent preliminary, unaudited estimates based on management's assessment of information available as of the conference call date. Halozyme stated the estimates are subject to completion of financial and accounting procedures, and final results could vary materially from these preliminary figures.

The company cautioned that the estimates should not substitute for financial information to be filed in its Form 10-K for the year ended December 31, 2025, once available. The Delaware-based biotechnology company also provided updated 2026 guidance during the investor call.

You May Also Be Interested In

• Ocean Power Technologies revises fiscal 2026 results after audit
• Coty (COTY) Misses Q4 EPS by 1c, offers outlook
• Rapid Line sees stock surge with no known corporate cause